PALM004: an observational study of the natural history of bundibugyo virus disease
Active Awarded
- Contract number
- 75N91026F00033
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $11,725,031
Award facts
- Contract value 100% obligated
- $11,725,031.00 Current and potential, with all options
- Completion date 3% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The National Institute of Allergy and Infectious Diseases issued a delivery order to Leidos Biomedical Research Inc. on September 25, 2026, with a ceiling value of $11.725 million for an observational study of the natural history of Bundibugyo virus disease.
The order flows from the NIAID master indefinite delivery vehicle HHSN261201500003I, which supports biomedical research execution, clinical trial support, and specialized manufacturing across the National Institutes of Health. Place of performance is Frederick, Maryland. The order carries a cost-plus-fixed-fee pricing structure with an ultimate completion date of September 24, 2029. Leidos Biomedical Research operates the Frederick National Laboratory for Cancer Research as a Federally Funded Research and Development Center and channels the majority of its federal workload through the two NIH master vehicles—NCI's master IDC and NIAID's vehicle—reflecting deep customer concentration in biomedical research infrastructure and clinical research support.
Quick answers
Who was awarded contract 75N91026F00033?
75N91026F00033 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 25, 2026.
How much is contract 75N91026F00033 worth?
The government has obligated $11,725,031 on 75N91026F00033.
Which agency awarded contract 75N91026F00033?
National Cancer Institute (National Institutes of Health) awarded 75N91026F00033, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91026F00033 an order under another contract?
Yes. 75N91026F00033 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91026F00033 competed?
The extent of competition for 75N91026F00033 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award